Literature DB >> 3111362

Failure to demonstrate a consistent in vitro bactericidal effect of trimethoprim-sulfamethoxazole against enterococci.

A Najjar, B E Murray.   

Abstract

Controversy exists as to the in vitro and in vivo activities of trimethoprim-sulfamethoxazole (TMP-SMX) against enterococci. In this study, we investigated the in vitro activity of TMP-SMX in the type of Mueller-Hinton broth previously reported to give the lowest MICs and MBCs with enterococci. In all instances, MICs were less than or equal to 0.5 microgram/ml. The majority of tests showed MBCs of greater than 32 micrograms/ml, although there was some effect from varying the inoculum and the length of incubation after subculturing. Minor differences were noted when tests were repeated and between the results from microdilution and macrodilution tests and those obtained by the time-kill method. These results, as well as other reports, suggest that TMP-SMX should not be considered a reliable bactericidal agent against enterococci.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3111362      PMCID: PMC174838          DOI: 10.1128/AAC.31.5.808

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Comparison of two beta-lactamase-producing strains of Streptococcus faecalis.

Authors:  B E Murray; D A Church; A Wanger; K Zscheck; M E Levison; M J Ingerman; E Abrutyn; B Mederski-Samoraj
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

2.  Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis.

Authors:  W R Wilson; C J Wilkowske; A J Wright; M A Sande; J E Geraci
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

3.  Optimal therapy for enterococcal endocarditis.

Authors:  J Herzstein; J L Ryan; R J Mangi; T P Greco; V T Andriole
Journal:  Am J Med       Date:  1984-02       Impact factor: 4.965

4.  Susceptibilities of enterococci to twelve antibiotics.

Authors:  R W Tofte; J A Solliday; K B Crossley
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

5.  Enterococci from Bangkok, Thailand, with high-level resistance to currently available aminoglycosides.

Authors:  B E Murray; J Tsao; J Panida
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

6.  Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis.

Authors:  B E Murray; B Mederski-Samaroj
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

7.  Susceptibility of enterococci to trimethoprim and trimethoprim-sulfamethoxazole.

Authors:  S R Crider; S D Colby
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

8.  In vivo v in vitro susceptibility of enterococcus to trimethoprim-sulfamethoxazole. A pitfall.

Authors:  G L Goodhart
Journal:  JAMA       Date:  1984-11-16       Impact factor: 56.272

9.  High-level resistance to gentamicin in clinical isolates of enterococci.

Authors:  B D Mederski-Samoraj; B E Murray
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

10.  Reversal of the in vitro susceptibility of enterococci to trimethoprim-sulfamethoxazole by folinic acid.

Authors:  M J Zervos; D R Schaberg
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

  10 in total
  12 in total

1.  Activity of LY146032 against Enterococci with and without high-level aminoglycoside resistance, including two penicillinase-producing strains.

Authors:  A R Wanger; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

2.  Characterization of dihydrofolate reductase genes from trimethoprim-susceptible and trimethoprim-resistant strains of Enterococcus faecalis.

Authors:  T M Coque; K V Singh; G M Weinstock; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Septicemia due to susceptible Enterococcus faecalis despite prophylaxis with trimethoprim-sulfamethoxazole.

Authors:  H A Elsner; W Krüger; R Laufs; D Mack
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-08       Impact factor: 3.267

Review 4.  Diversity among multidrug-resistant enterococci.

Authors:  B E Murray
Journal:  Emerg Infect Dis       Date:  1998 Jan-Mar       Impact factor: 6.883

5.  Antibiotic treatment of enterococcal infections.

Authors:  B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 6.  Trimethoprim resistance.

Authors:  P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

7.  Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole?

Authors:  Asha C Bowen; Rachael A Lilliebridge; Steven Y C Tong; Robert W Baird; Peter Ward; Malcolm I McDonald; Bart J Currie; Jonathan R Carapetis
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

Review 8.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

9.  In Vivo and In Vitro Effects of a ClpP-Activating Antibiotic against Vancomycin-Resistant Enterococci.

Authors:  Autumn Brown Gandt; Elizabeth C Griffith; Ida M Lister; Lisa L Billings; Angel Han; Rajendra Tangallapally; Ying Zhao; Aman P Singh; Richard E Lee; Michael D LaFleur
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

10.  Lack of homology of enterococci which have high-level resistance to trimethoprim with the dfrA gene of Staphylococcus aureus.

Authors:  M Frosolono; S L Hodel-Christian; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.